News
Click here for news in Danish.
November 22, 2017 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise November 21, 2017 | Company Announcements
Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox VaccineNovember 09, 2017 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV VaccineNovember 08, 2017 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 September 27, 2017 | Company Announcements
Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. GovernmentSeptember 21, 2017 | Company Announcements
Bavarian Nordic Provides Update on its Universal RSV VaccineSeptember 14, 2017 | Company Announcements
Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic’s Phase 3 Study of PROSTVAC in Metastatic Prostate CancerSeptember 14, 2017 | Press Releases
Bavarian Nordic to Host Capital Markets Day in New York CitySeptember 11, 2017 | Press Releases
Principal Investigator Dr. James Gulley to Provide Presentation Entitled “Therapeutic Vaccines in Prostate Cancer” at the ESMO 2017 Congress August 25, 2017 | Company Announcements
Bavarian Nordic Announces First Half 2017 ResultsAugust 22, 2017 | Company Announcements
Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation – JJDC, Inc.August 21, 2017 | Company Announcements
Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation – JJDC, Inc. August 09, 2017 | Company Announcements
Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation – JJDC, Inc.July 27, 2017 | Company Announcements
Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation – JJDC, Inc.July 27, 2017 | Company Announcements
Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis BJuly 03, 2017 | Company Announcements
Bavarian Nordic Issues Warrants to Newly Appointed Member of the Executive Management June 27, 2017 | Company Announcements
Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV VaccineJune 16, 2017 | Company Announcements
Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNEJune 16, 2017 | Company Announcements
Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT StudyMay 19, 2017 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 18, 2017 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise May 18, 2017 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 10, 2017 | Company Announcements
Bavarian Nordic Announces Appointment of Dr. Tommi Kainu as Chief Business Officer May 04, 2017 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2017 April 25, 2017 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 25, 2017